Guideline No. 425a: Cannabis Use Throughout Women’s Lifespans – Part 1: Fertility, Contraception, Menopause, and Pelvic Pain



      To provide health care providers with the best evidence on cannabis use with respect to women’s health. Areas of focus include general patterns of cannabis use as well as safety of use; care for women who use cannabis; stigma; screening, brief intervention, and referral to treatment; impact on hormonal regulation; reproductive health, including contraception and fertility; sexual function; effects on perimenopausal and menopausal symptoms; and use in chronic pelvic pain syndromes.

      Target Population

      The target population includes all women currently using or contemplating using cannabis.


      Open, evidence-informed dialogue about cannabis use, which will lead to improvement in patient care.

      Benefits, Harms, and Costs

      Exploring cannabis use through a trauma-informed approach provides the health care provider and patient with an opportunity to build a strong, collaborative, therapeutic alliance. This alliance empowers women to make informed choices about their own care. It also allows for the diagnosis and possible treatment of cannabis use disorders. Use should not be stigmatized, as stigma leads to poor “partnered care” (i.e., the partnership between the patient and care provider). Multiple side effects of cannabis use may be mistaken for other disorders. Currently, use of cannabis to treat women’s health issues is not covered by public funding; as a result, individual users must pay the direct cost. The indirect costs of cannabis use are unknown. Thus, health care providers and patients must understand the role of cannabis in women’s health issues, so that women can make knowledgeable decisions.


      PubMed, EMBASE, and grey literature were searched to identify studies of “cannabis use and effect on infertility, contraception, perimenopause and menopausal symptoms, and pelvic pain” published between January 1, 2018 and February 18, 2021. All clinical trials, observational studies, reviews (including systematic reviews and meta-analyses), guidelines, and conference consensus statements were included. Publications were screened for relevance. The search terms were developed using the Medical Subject Headings (MeSH) terms and keywords (and variants), including cannabis, cannabinoids, marijuana, dexanabinol, dronabinol, tetrahydrocannabinol; the specific terms to capture women’s health were estrogen, estradiol, medroxyprogesterone acetate, vaginal contraception, oral contraceptives, fertilization, amenorrhea, oligomenorrhea, pelvic pain, dysmenorrhea, endometriosis, interstitial cystitis, vulvodynia, and menopause.

      Validation Methods

      The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and weak recommendations).

      Intended Audience

      All heath care providers who care for women.


      • 1.
        Cannabis use is increasing, and women are commonly using cannabis for recreational and medical reasons (high).
      • 2.
        Use of cannabis, especially products containing tetrahydrocannabinol, can induce or worsen psychosis and worsen depression (high).
      • 3.
        Study results concerning the association between cannabis and anxiety are conflicting, and this association requires further evaluation (high).
      • 4.
        Use of cannabis, similar to use of other intoxicating substances, may be associated with high-risk sexual activity (low).
      • 5.
        There is no evidence that contraceptive methods are altered by cannabis use (low).
      • 6.
        There is limited evidence that frequent cannabis use may affect female fertility (moderate), but frequent use can diminish male fertility (moderate).
      • 7.
        There is no evidence for cannabis use for management of perimenopausal symptoms (very low).
      • 8.
        There is no evidence that cannabis products improve chronic pelvic pain (low).


      • 1.
        Women should be screened for cannabis use, as they are for other substance use (strong, moderate), and further exploration of its impact should be initiated (strong, moderate).
      • 2.
        Cannabis use can be screened for using appropriate screening tools (conditional, moderate)
      • 3.
        A trauma-informed care approach and harm reduction should be used when inquiring about cannabis use (strong, low).
      • 4.
        The fact that a woman uses cannabis should not influence her choice of contraceptive method (strong, moderate).
      • 5.
        Couples should be counselled that cannabis use appears to affect male fertility and may have an impact on female fertility (conditional, moderate).
      • 6.
        Sleep disturbances in the perimenopausal period should be characterized and other management modalities trialed before women consider using any cannabis product for this indication (strong, moderate).
      • 7.
        Women should be counselled about the lack of evidence for using cannabis products to treat chronic pelvic pain (strong, moderate).



      2-AG (2-arachidonoyl glycerol), CB1 (cannabinoid 1), CB2 (cannabinoid 2), CBD (cannabidiol), CUDIT-R (Cannabis Use Disorder Identification Test Revised), CYP (cytochrome P450), GABA (gamma-aminobutyric acid), GnRH (gonadotropin-releasing hormone), mRNA (messenger ribonucleic acid), PTSD (post traumatic stress disorder), Δ9-THC or THC (delta-9-tetrahydrocannabinol), SBIRT (Screening, Brief Intervention and Referral to Treatment), TRH (thyrotropin-releasing hormone), TrpV1 (transient receptor potential cation channel subfamily V member 1)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Health Canada
        Canadian Cannabis Survey 2020: Summary.
        2020 (Available at)
        • Health Canada
        The Canadian Cannabis Survey Methodological Report.
        2017 (Available at)
        • Health Canada
        The Canadian Cannabis Survey 2018 Methodological Report.
        2018 (Available at)
        • Health Canada
        Canadian Cannabis Survey 2019 summary (Table 13).
        2019 (Available at)
        • Health Canada
        Summary of results: Canadian Student Tobacco, Alcohol and Drugs Survey 2018-2019.
        2019 (Available at)
        • Graves L.
        • Robert M.
        • Allen V.
        • et al.
        Guideline No. 425b: Cannabis Use Throughout Women's Lifespans – Part 2: Pregnancy, the Postnatal Period and Breastfeeding.
        J Obstet Gynaecol Can. 2022; 44: 436-444
        • Kosiba J.D.
        • Maisto S.A.
        • Ditre J.W.
        Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.
        Soc Sci Med. 2019; 233: 181-192
        • Kasman A.M.
        • Bhambhvani H.P.
        • Wilson-King G.
        • et al.
        Assessment of the Association of Cannabis on Female Sexual Function With the Female Sexual Function Index.
        Sex Med. 2020; 8: 699-708
        • Cooper Z.D.
        • Craft R.M.
        Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.
        Neuropsychopharmacology. 2018; 43: 34-51
        • Hernandez-Avila C.A.
        • Rounsaville B.J.
        • Kranzler H.R.
        Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment.
        Drug Alcohol Depend. 2004; 74: 265-272
        • Piazza N.J.
        • Vrbka J.L.
        • Yeager R.D.
        Telescoping of alcoholism in women alcoholics.
        Int J Addict. 1989; 24: 19-28
        • Greaves L.
        • Hemsing N.
        Sex and gender interactions on the use and impact of recreational cannabis.
        Int J Environ Res Public Health. 2020; 17: 509
        • Pertwee R.G.
        The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
        Br J Pharmacol. 2008; 153: 199-215
        • Zou S.
        • Kumar U.
        Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.
        Int J Mol Sci. 2018; 19
        • Friedman D.
        • French J.A.
        • Maccarrone M.
        Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
        Lancet Neurol. 2019; 18: 504-512
        • Devinsky O.
        • Cilio M.R.
        • Cross H.
        • et al.
        Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
        Epilepsia. 2014; 55: 791-802
        • Huestis M.A.
        Human cannabinoid pharmacokinetics.
        Chem Biodivers. 2007; 4: 1770-1804
        • Grotenhermen F.
        Pharmacokinetics and pharmacodynamics of cannabinoids.
        Clin Pharmacokinet. 2003; 42: 327-360
        • Karschner E.L.
        • DarwinP W.D.
        • McMahon R.P.
        • et al.
        Subjective and physiological effects after controlled Sativex and oral THC administration.
        Clin Pharmacol Ther. 2011; 89: 400-407
        • Gabrys R.
        Clearing the smoke on cannabis: Edible cannabis products, cannabis extracts and cannabis topicals.
        (Canadian Centre on Substance Use and Addiction [Internet])2020 (Available at)
      1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA2013.

        • Beirness D.J.
        • Porath A.J.
        Clearing the Smoke on Cannabis: Cannabis Use and Driving - An Update.
        (Canadian Centre on Substance Use and Addiction [Internet])2019 (Available at)
        • Government of Canada
        Cannabis poisoning.
        2019 (Available at)
        • Marconi A.
        • Di Forti M.
        • Lewis C.M.
        • et al.
        Meta-analysis of the association between the level of cannabis use and risk of psychosis.
        Schizophr Bull. 2016; 42: 1262-1269
        • van der Steur S.J.
        • Batalla A.
        • Bossong M.G.
        Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.
        Brain Sci. 2020; 10: 1-17
        • Schoeler T.
        • Monk A.
        • Sami M.B.
        • et al.
        Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.
        Lancet Psychiatry. 2016; 3: 215-225
        • Gobbi G.
        • Atkin T.
        • Zytynski T.
        • et al.
        Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis.
        JAMA Psychiatry. 2019; 76: 426-434
        • Hengartner M.P.
        • Angst J.
        • Ajdacic-Gross V.
        • et al.
        Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years.
        J Affect Disord. 2020; 272: 98-103
        • Han B.
        • Compton W.M.
        • Einstein E.B.
        • et al.
        Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status.
        JAMA Network Open. 2021; 4e2113025-e
        • Kedzior K.K.
        • Laeber L.T.
        A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.
        BMC Psychiatry. 2014; 14: 136
        • Feingold D.
        • Weiser M.
        • Rehm J.
        • et al.
        The association between cannabis use and anxiety disorders: Results from a population-based representative sample.
        Eur Neuropsychopharmacol. 2016; 26: 493-505
        • Van Ameringen M.
        • Zhang J.
        • Patterson B.
        • et al.
        The role of cannabis in treating anxiety: an update.
        Curr Opin Psychiatry. 2020; 33: 1-7
        • Buckner J.D.
        • Heimberg R.G.
        • Schneier F.R.
        • et al.
        The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC).
        Drug Alcohol Depend. 2012; 124: 128-134
        • Kevorkian S.
        • Bonn-Miller M.O.
        • Belendiuk K.
        • et al.
        Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample.
        Psychol Addict Behav. 2015; 29: 633-638
        • Gabrys R.
        • Porath A.
        Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning.
        (Canadian Centre on Substance Use and Addiction [Internet])2019 (Available at)
        • Renard J.
        Clearing the smoke on cannabis: Respiratory and cardiovascular effects of cannabis smoking.
        (Canadian Centre on Substance Use and Addiction [Internet])2020 (Available at)
        • Agrawal A.
        • Few L.
        • Nelson E.C.
        • et al.
        Adolescent cannabis use and repeated voluntary unprotected sex in women.
        Addiction. 2016; 111: 2012-2020
        • Brodbeck J.
        • Matter M.
        • Moggi F.
        Association between cannabis use and sexual risk behavior among young heterosexual adults.
        AIDS Behav. 2006; 10: 599-605
        • Zhang X.
        • Wu L.T.
        Marijuana use and sex with multiple partners among lesbian, gay and bisexual youth: results from a national sample.
        BMC Public Health. 2017; 17: 19
        • Smith A.M.
        • Ferris J.A.
        • Simpson J.M.
        • et al.
        Cannabis use and sexual health.
        J Sex Med. 2010; 7: 787-793
        • Duff C.
        • Erickson P.G.
        Cannabis, risk and normalisation: evidence from a Canadian study of socially integrated, adult cannabis users.
        Health Risk Soc. 2014; 16: 210-226
        • Hemsing N.
        • Greaves L.
        Gender norms, roles and relations and cannabis-use patterns: A scoping review.
        Int J Environ Res Public Health. 2020; 17: 947
        • Piper B.J.
        • Beals M.L.
        • Abess A.T.
        • et al.
        Chronic pain patients' perspectives of medical cannabis.
        Pain. 2017; 158: 1373-1379
        • Bottorff J.L.
        • Bissell L.J.
        • Balneaves L.G.
        • et al.
        Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study.
        Harm Reduct J. 2013; 10: 2
        • Leos-Toro C.
        • Shiplo S.
        • Hammond D.
        Perceived support for medical cannabis use among approved medical cannabis users in Canada.
        Drug Alcohol Rev. 2018; 37: 627-636
        • NANOS, Canadian Centre on Substance Abuse
        The majority of Canadians don't plan to consume legal cannabis, Canadian insights into cannabis legalization: CCSA September OMNI Survey Summary - FINAL.
        2018 (Available at)
        • Adamson S.J.
        • Kay-Lambkin F.J.
        • Baker A.L.
        • et al.
        An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R).
        Drug Alcohol Depend. 2010; 110: 137-143
        • Shogren M.D.
        • Harsell C.
        • Heitkamp T.
        Screening Women for At-Risk Alcohol Use: An Introduction to Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Women's Health.
        J Midwifery Womens Health. 2017; 62: 746-754
        • Babor T.F.
        • Del Boca F.
        • Bray J.W.
        Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice.
        Addiction. 2017; 112 Suppl 2: 110-117
        • Gilinsky A.
        • Swanson V.
        • Power K.
        Interventions delivered during antenatal care to reduce alcohol consumption during pregnancy: A systematic review.
        Addict Res Theory. 2011; 19: 235-250
        • Miller W.
        • Rollnick S.
        Motiviational Inteviewing: Helping People Change.
        3rd ed. Guilford Press, New York2012
        • Osterman R.L.
        • Carle A.C.
        • Ammerman R.T.
        • et al.
        Single-session motivational intervention to decrease alcohol use during pregnancy.
        J Subst Abuse Treat. 2014; 47: 10-19
        • Rubak S.
        • Sandbaek A.
        • Lauritzen T.
        • et al.
        Motivational interviewing: a systematic review and meta-analysis.
        Br J Gen Pract. 2005; 55: 305-312
        • Canadian Centre on Substance Abuse
        Trauma-informed Care (The Essentials of ... Series).
        2014 (Available at)
        • Purkey E.
        • Patel R.
        • Phillips S.P.
        Trauma-informed care: Better care for everyone.
        Can Fam Physician. 2018; 64: 170-172
        • Cunradi C.B.
        • Caetano R.
        • Alter H.J.
        • et al.
        Adverse childhood experiences are associated with at-risk drinking, cannabis and illicit drug use in females but not males: an Emergency Department study.
        Am J Drug Alcohol Abuse. 2020; : 1-10
        • Thomas G.
        Harm Reduction Policies and Programs Involved for Persons Involved in the Criminal Justice System.
        2005 (Available at)
      2. Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products.

        • Fischer B.
        • Russell C.
        • Sabioni P.
        • et al.
        Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.
        Am J Public Health. 2017; 107: e1-e12
        • Brents L.K.
        Marijuana, the Endocannabinoid System and the Female Reproductive System.
        Yale J Biol Med. 2016; 89: 175-191
        • Dobovisek L.
        • Hojnik M.
        • Ferk P.
        Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review).
        Int J Mol Med. 2016; 38: 1642-1651
        • Walker O.S.
        • Holloway A.C.
        • Raha S.
        The role of the endocannabinoid system in female reproductive tissues.
        J Ovarian Res. 2019; 12: 3
        • Asch R.H.
        • Smith C.G.
        • Siler-Khodr T.M.
        • et al.
        Effects of delta 9-tetraphydrocannabinol administration on gonadal steroidogenic activity in vivo.
        Fertil Steril. 1979; 32: 576-582
        • Smith C.G.
        • Almirez R.G.
        • Berenberg J.
        • et al.
        Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle.
        Science. 1983; 219: 1453-1455
        • Jukic A.M.
        • Weinberg C.R.
        • Baird D.D.
        • et al.
        Lifestyle and reproductive factors associated with follicular phase length.
        J Womens Health (Larchmt). 2007; 16: 1340-1347
        • Lammert S.
        • Harrison K.
        • Tosun N.
        • et al.
        Menstrual Cycle in Women Who Co-use Marijuana and Tobacco.
        J Addict Med. 2018; 12: 207-211
        • Cecconi S.
        • Rapino C.
        • Di Nisio V.
        • et al.
        The (endo)cannabinoid signaling in female reproduction: What are the latest advances?.
        Prog Lipid Res. 2020; 77: 101019
        • Friedrich J.
        • Khatib D.
        • Parsa K.
        • et al.
        The grass isn't always greener: The effects of cannabis on embryological development.
        BMC Pharmacol Toxicol. 2016; 17: 45
        • Neradugomma N.K.
        • Drafton K.
        • Mor G.G.
        • et al.
        Marijuana-derived cannabinoids inhibit uterine endometrial stromal cell decidualization and compromise trophoblast-endometrium cross-talk.
        Reprod Toxicol. 2019; 87: 100-107
        • Almada M.
        • Amaral C.
        • Oliveira A.
        • et al.
        Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling.
        Reprod Toxicol. 2020; 93: 75-82
        • Zendulka O.
        • Dovrtelova G.
        • Noskova K.
        • et al.
        Cannabinoids and Cytochrome P450 Interactions.
        Curr Drug Metab. 2016; 17: 206-226
        • Choi S.Y.
        • Koh K.H.
        • Jeong H.
        Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone.
        Drug Metab Dispos. 2013; 41: 263-269
        • Black A.
        • Guilbert E.
        • Co A.
        • et al.
        Canadian Contraception Consensus (Part 1 of 4).
        J Obstet Gynaecol Can. 2015; 37: 936-942
        • Jordan T.
        • Ngo B.
        • Jones C.A.
        The use of cannabis and perceptions of its effect on fertility among infertility patients.
        Hum Reprod Open. 2020; 2020: hoz041
        • Battista N.
        • Bari M.
        • Maccarrone M.
        Endocannabinoids and Reproductive Events in Health and Disease.
        Handb Exp Pharmacol. 2015; 231: 341-365
        • Mumford S.L.
        • Flannagan K.S.
        • Radoc J.G.
        • et al.
        Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss.
        Hum Reprod. 2021; 36: 1405-1415
        • Payne K.S.
        • Mazur D.J.
        • Hotaling J.M.
        • et al.
        Cannabis and Male Fertility: A Systematic Review.
        J Urol. 2019; 202: 674-681
        • Carvalho R.K.
        • Souza M.R.
        • Santos M.L.
        • et al.
        Chronic cannabidiol exposure promotes functional impairment in sexual behavior and fertility of male mice.
        Reprod Toxicol. 2018; 81: 34-40
        • Lynn B.
        • Gee A.
        • Zhang L.
        • et al.
        Effects of Cannabinoids on Female Sexual Function.
        Sex Med Rev. 2020; 8: 18-27
        • Lynn B.K.
        • Lopez J.D.
        • Miller C.
        • et al.
        The Relationship between Marijuana Use Prior to Sex and Sexual Function in Women.
        Sex Med. 2019; 7: 192-197
        • Gorzalka B.B.
        • Hill M.N.
        • Chang S.C.
        Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function.
        Horm Behav. 2010; 58: 91-99
        • Kicman A.
        • Toczek M.
        The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease.
        Int J Mol Sci. 2020; 21
        • Ladha K.S.
        • Manoo V.
        • Virji A.F.
        • et al.
        The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.
        Cannabis Cannabinoid Res. 2019; 4: 219-230
        • Slavin M.
        • Barach E.
        • Farmer S.
        • et al.
        Cannabis and symptoms of PMS and PMDD.
        Addict Res Theory. 2017; 25: 383-389
        • Babson K.A.
        • Sottile J.
        • Morabito D.
        Cannabis, Cannabinoids, and Sleep: a Review of the Literature.
        Curr Psychiatry Rep. 2017; 19: 23
        • Verrilli L.
        • Berga S.L.
        What Every Gynecologist Should Know About Perimenopause.
        Clin Obstet Gynecol. 2020; 63: 720-734
        • Black N.
        • Stockings E.
        • Campbell G.
        • et al.
        Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
        Lancet Psychiatry. 2019; 6: 995-1010
        • Idris A.I.
        • van 't Hof R.J.
        • Greig I.R.
        • et al.
        Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.
        Nat Med. 2005; 11: 774-779
        • Stockings E.
        • Campbell G.
        • Hall W.D.
        • et al.
        Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies.
        Pain. 2018; 159: 1932-1954
        • Donvito G.
        • Nass S.R.
        • Wilkerson J.L.
        • et al.
        The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.
        Neuropsychopharmacology. 2018; 43: 52-79
        • Tanaka K.
        • Mayne L.
        • Khalil A.
        • et al.
        The role of the endocannabinoid system in aetiopathogenesis of endometriosis: A potential therapeutic target.
        Eur J Obstet Gynecol Reprod Biol. 2020; 244: 87-94
        • Sinclair J.
        • Smith C.A.
        • Abbott J.
        • et al.
        Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey.
        J Obstet Gynaecol Can. 2020; 42: 256-261
        • Geoffrion R.
        • Yang E.C.
        • Koenig N.A.
        • et al.
        Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain.
        Obstet Gynecol. 2021; 137: 91-99
        • Shen X.
        • Duan H.
        • Wang S.
        • et al.
        Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis.
        Reprod Sci. 2019; 26: 1618-1625
        • Shen X.
        • Duan H.
        • Wang S.
        • et al.
        Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.
        Biomed Res Int. 2019; 2019: 5468954
        • Boo B.
        • Kamath R.
        • Arriaga-Gomez E.
        • et al.
        Tetrahydrocannabinol Reduces Hapten-Driven Mast Cell Accumulation and Persistent Tactile Sensitivity in Mouse Model of Allergen-Provoked Localized Vulvodynia.
        Int J Mol Sci. 2019; 20
        • Pham M.N.
        • Hudnall M.T.
        • Nadler R.B.
        Marijuana, lower urinary tract symptoms, and pain in the urologic patient.
        Urology. 2020;
        • Hasin D.S.
        • Keyes K.M.
        • Alderson D.
        • et al.
        Cannabis withdrawal in the United States: results from NESARC.
        J Clin Psychiatry. 2008; 69: 1354-1363
        • Levin K.H.
        • Copersino M.L.
        • Heishman S.J.
        • et al.
        Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.
        Drug Alcohol Depend. 2010; 111: 120-127
        • Brezing C.A.
        • Levin F.R.
        The current state of pharmacological treatments for cannabis use disorder and withdrawal.
        Neuropsychopharmacology. 2018; 43: 173-194
        • Ladha K.S.
        • McLaren-Blades A.
        • Goel A.
        • et al.
        Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process.
        Br J Anaesth. 2021; 126: 304-318
        • White C.M.
        A review of human studies assessing cannabidiol's (CBD) therapeutic actions and potential.
        J Clin Pharmacol. 2019; 59: 923-934


        • Newmeyer M.N.
        • Swortwood M.J.
        • Barnes A.J.
        • et al.
        Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: Identification of recent cannabis intake.
        Clin Chem. 2016; 62 (Available at): 1579-1592
        • Spindle T.R.
        • Cone E.J.
        • Schlienz N.J.
        • et al.
        Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: A crossover trial.
        JAMA Netw Open. 2018; 1 (Available at)e184841
        • Grotenhermen F.
        Pharmacokinetics and pharmacodynamics of cannabinoids.
        Clin Pharmacokinet. 2003; 42 (Available at): 327-360
        • Huestis M.A.
        Human cannabinoid pharmacokinetics.
        Chem Biodivers. 2007; 4 (Available at): 1770-1804
        • Spindle T.R.
        • Cone E.J.
        • Schlienz N.J.
        • et al.
        Urinary excretion profile of 11-nor-9-carboxy-delta9-tetrahydrocannabinol (thccooh) following smoked and vaporized cannabis administration in infrequent cannabis users.
        J Anal Toxicol. 2020; 44 (Available at): 1-14
        • Matheson J.
        • Sproule B.
        • Di Ciano P.
        • et al.
        Sex differences in the acute effects of smoked cannabis: Evidence from a human laboratory study of young adults.
        Psychopharmacology (Berl). 2020; 237 (Available at): 305-316
        • Spindle T.R.
        • Cone E.J.
        • Goffi E.
        • et al.
        Pharmacodynamic effects of vaporized and oral cannabidiol (cbd) and vaporized cbd-dominant cannabis in infrequent cannabis users.
        Drug Alcohol Depend. 2020; 211 (Available at): 107937
        • Chadi N.
        • Minato C.
        • Stanwick R.
        Cannabis vaping: Understanding the health risks of a rapidly emerging trend.
        Paediatrics & Child Health. 2020; 25 (Available at. S16-S20
        • Millar S.A.
        • Stone N.L.
        • Yates A.S.
        • et al.
        A systematic review on the pharmacokinetics of cannabidiol in humans.
        Front Pharmacol. 2018; 9 (Available at): 1365
        • Vandrey R.
        • Herrmann E.S.
        • Mitchell J.M.
        • et al.
        Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes.
        J Anal Toxicol. 2017; 41 (Available at): 83-99
        • Karschner E.L.
        • Darwin W.D.
        • McMahon R.P.
        • et al.
        Subjective and physiological effects after controlled sativex and oral thc administration.
        Clin Pharmacol Ther. 2011; 89: 400-407

      Linked Article